Cargando…

Whole-Body [(18)F]FDG PET/CT Can Alter Diagnosis in Patients with Suspected Rheumatic Disease

The 2-deoxy-d-[(18)F]fluoro-D-glucose (FDG) positron emission tomography/computed tomography (PET/CT) is widely utilized to assess the vascular and articular inflammatory burden of patients with a suspected diagnosis of rheumatic disease. We aimed to elucidate the impact of [(18)F]FDG PET/CT on chan...

Descripción completa

Detalles Bibliográficos
Autores principales: Fröhlich, Matthias, Serfling, Sebastian, Higuchi, Takahiro, Pomper, Martin G., Rowe, Steven P., Schmalzing, Marc, Tony, Hans-Peter, Gernert, Michael, Strunz, Patrick-Pascal, Portegys, Jan, Schwaneck, Eva-Christina, Gadeholt, Ottar, Weich, Alexander, Buck, Andreas K., Bley, Thorsten A., Guggenberger, Konstanze V., Werner, Rudolf A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8625716/
https://www.ncbi.nlm.nih.gov/pubmed/34829421
http://dx.doi.org/10.3390/diagnostics11112073
_version_ 1784606489607929856
author Fröhlich, Matthias
Serfling, Sebastian
Higuchi, Takahiro
Pomper, Martin G.
Rowe, Steven P.
Schmalzing, Marc
Tony, Hans-Peter
Gernert, Michael
Strunz, Patrick-Pascal
Portegys, Jan
Schwaneck, Eva-Christina
Gadeholt, Ottar
Weich, Alexander
Buck, Andreas K.
Bley, Thorsten A.
Guggenberger, Konstanze V.
Werner, Rudolf A.
author_facet Fröhlich, Matthias
Serfling, Sebastian
Higuchi, Takahiro
Pomper, Martin G.
Rowe, Steven P.
Schmalzing, Marc
Tony, Hans-Peter
Gernert, Michael
Strunz, Patrick-Pascal
Portegys, Jan
Schwaneck, Eva-Christina
Gadeholt, Ottar
Weich, Alexander
Buck, Andreas K.
Bley, Thorsten A.
Guggenberger, Konstanze V.
Werner, Rudolf A.
author_sort Fröhlich, Matthias
collection PubMed
description The 2-deoxy-d-[(18)F]fluoro-D-glucose (FDG) positron emission tomography/computed tomography (PET/CT) is widely utilized to assess the vascular and articular inflammatory burden of patients with a suspected diagnosis of rheumatic disease. We aimed to elucidate the impact of [(18)F]FDG PET/CT on change in initially suspected diagnosis in patients at the time of the scan. Thirty-four patients, who had undergone [(18)F]FDG PET/CT, were enrolled and the initially suspected diagnosis prior to [(18)F]FDG PET/CT was compared to the final diagnosis. In addition, a semi-quantitative analysis including vessel wall-to-liver (VLR) and joint-to-liver (JLR) ratios was also conducted. Prior to [(18)F]FDG PET/CT, 22/34 (64.7%) of patients did not have an established diagnosis, whereas in 7/34 (20.6%), polymyalgia rheumatica (PMR) was suspected, and in 5/34 (14.7%), giant cell arteritis (GCA) was suspected by the referring rheumatologists. After [(18)F]FDG PET/CT, the diagnosis was GCA in 19/34 (55.9%), combined GCA and PMR (GCA + PMR) in 9/34 (26.5%) and PMR in the remaining 6/34 (17.6%). As such, [(18)F]FDG PET/CT altered suspected diagnosis in 28/34 (82.4%), including in all unclear cases. VLR of patients whose final diagnosis was GCA tended to be significantly higher when compared to VLR in PMR (GCA, 1.01 ± 0.08 (95%CI, 0.95–1.1) vs. PMR, 0.92 ± 0.1 (95%CI, 0.85–0.99), p = 0.07), but not when compared to PMR + GCA (1.04 ± 0.14 (95%CI, 0.95–1.13), p = 1). JLR of individuals finally diagnosed with PMR (0.94 ± 0.16, (95%CI, 0.83–1.06)), however, was significantly increased relative to JLR in GCA (0.58 ± 0.04 (95%CI, 0.55–0.61)) and GCA + PMR (0.64 ± 0.09 (95%CI, 0.57–0.71); p < 0.0001, respectively). In individuals with a suspected diagnosis of rheumatic disease, an inflammatory-directed [(18)F]FDG PET/CT can alter diagnosis in the majority of the cases, particularly in subjects who were referred because of diagnostic uncertainty. Semi-quantitative assessment may be helpful in establishing a final diagnosis of PMR, supporting the notion that a quantitative whole-body read-out may be useful in unclear cases.
format Online
Article
Text
id pubmed-8625716
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-86257162021-11-27 Whole-Body [(18)F]FDG PET/CT Can Alter Diagnosis in Patients with Suspected Rheumatic Disease Fröhlich, Matthias Serfling, Sebastian Higuchi, Takahiro Pomper, Martin G. Rowe, Steven P. Schmalzing, Marc Tony, Hans-Peter Gernert, Michael Strunz, Patrick-Pascal Portegys, Jan Schwaneck, Eva-Christina Gadeholt, Ottar Weich, Alexander Buck, Andreas K. Bley, Thorsten A. Guggenberger, Konstanze V. Werner, Rudolf A. Diagnostics (Basel) Article The 2-deoxy-d-[(18)F]fluoro-D-glucose (FDG) positron emission tomography/computed tomography (PET/CT) is widely utilized to assess the vascular and articular inflammatory burden of patients with a suspected diagnosis of rheumatic disease. We aimed to elucidate the impact of [(18)F]FDG PET/CT on change in initially suspected diagnosis in patients at the time of the scan. Thirty-four patients, who had undergone [(18)F]FDG PET/CT, were enrolled and the initially suspected diagnosis prior to [(18)F]FDG PET/CT was compared to the final diagnosis. In addition, a semi-quantitative analysis including vessel wall-to-liver (VLR) and joint-to-liver (JLR) ratios was also conducted. Prior to [(18)F]FDG PET/CT, 22/34 (64.7%) of patients did not have an established diagnosis, whereas in 7/34 (20.6%), polymyalgia rheumatica (PMR) was suspected, and in 5/34 (14.7%), giant cell arteritis (GCA) was suspected by the referring rheumatologists. After [(18)F]FDG PET/CT, the diagnosis was GCA in 19/34 (55.9%), combined GCA and PMR (GCA + PMR) in 9/34 (26.5%) and PMR in the remaining 6/34 (17.6%). As such, [(18)F]FDG PET/CT altered suspected diagnosis in 28/34 (82.4%), including in all unclear cases. VLR of patients whose final diagnosis was GCA tended to be significantly higher when compared to VLR in PMR (GCA, 1.01 ± 0.08 (95%CI, 0.95–1.1) vs. PMR, 0.92 ± 0.1 (95%CI, 0.85–0.99), p = 0.07), but not when compared to PMR + GCA (1.04 ± 0.14 (95%CI, 0.95–1.13), p = 1). JLR of individuals finally diagnosed with PMR (0.94 ± 0.16, (95%CI, 0.83–1.06)), however, was significantly increased relative to JLR in GCA (0.58 ± 0.04 (95%CI, 0.55–0.61)) and GCA + PMR (0.64 ± 0.09 (95%CI, 0.57–0.71); p < 0.0001, respectively). In individuals with a suspected diagnosis of rheumatic disease, an inflammatory-directed [(18)F]FDG PET/CT can alter diagnosis in the majority of the cases, particularly in subjects who were referred because of diagnostic uncertainty. Semi-quantitative assessment may be helpful in establishing a final diagnosis of PMR, supporting the notion that a quantitative whole-body read-out may be useful in unclear cases. MDPI 2021-11-09 /pmc/articles/PMC8625716/ /pubmed/34829421 http://dx.doi.org/10.3390/diagnostics11112073 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Fröhlich, Matthias
Serfling, Sebastian
Higuchi, Takahiro
Pomper, Martin G.
Rowe, Steven P.
Schmalzing, Marc
Tony, Hans-Peter
Gernert, Michael
Strunz, Patrick-Pascal
Portegys, Jan
Schwaneck, Eva-Christina
Gadeholt, Ottar
Weich, Alexander
Buck, Andreas K.
Bley, Thorsten A.
Guggenberger, Konstanze V.
Werner, Rudolf A.
Whole-Body [(18)F]FDG PET/CT Can Alter Diagnosis in Patients with Suspected Rheumatic Disease
title Whole-Body [(18)F]FDG PET/CT Can Alter Diagnosis in Patients with Suspected Rheumatic Disease
title_full Whole-Body [(18)F]FDG PET/CT Can Alter Diagnosis in Patients with Suspected Rheumatic Disease
title_fullStr Whole-Body [(18)F]FDG PET/CT Can Alter Diagnosis in Patients with Suspected Rheumatic Disease
title_full_unstemmed Whole-Body [(18)F]FDG PET/CT Can Alter Diagnosis in Patients with Suspected Rheumatic Disease
title_short Whole-Body [(18)F]FDG PET/CT Can Alter Diagnosis in Patients with Suspected Rheumatic Disease
title_sort whole-body [(18)f]fdg pet/ct can alter diagnosis in patients with suspected rheumatic disease
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8625716/
https://www.ncbi.nlm.nih.gov/pubmed/34829421
http://dx.doi.org/10.3390/diagnostics11112073
work_keys_str_mv AT frohlichmatthias wholebody18ffdgpetctcanalterdiagnosisinpatientswithsuspectedrheumaticdisease
AT serflingsebastian wholebody18ffdgpetctcanalterdiagnosisinpatientswithsuspectedrheumaticdisease
AT higuchitakahiro wholebody18ffdgpetctcanalterdiagnosisinpatientswithsuspectedrheumaticdisease
AT pompermarting wholebody18ffdgpetctcanalterdiagnosisinpatientswithsuspectedrheumaticdisease
AT rowestevenp wholebody18ffdgpetctcanalterdiagnosisinpatientswithsuspectedrheumaticdisease
AT schmalzingmarc wholebody18ffdgpetctcanalterdiagnosisinpatientswithsuspectedrheumaticdisease
AT tonyhanspeter wholebody18ffdgpetctcanalterdiagnosisinpatientswithsuspectedrheumaticdisease
AT gernertmichael wholebody18ffdgpetctcanalterdiagnosisinpatientswithsuspectedrheumaticdisease
AT strunzpatrickpascal wholebody18ffdgpetctcanalterdiagnosisinpatientswithsuspectedrheumaticdisease
AT portegysjan wholebody18ffdgpetctcanalterdiagnosisinpatientswithsuspectedrheumaticdisease
AT schwaneckevachristina wholebody18ffdgpetctcanalterdiagnosisinpatientswithsuspectedrheumaticdisease
AT gadeholtottar wholebody18ffdgpetctcanalterdiagnosisinpatientswithsuspectedrheumaticdisease
AT weichalexander wholebody18ffdgpetctcanalterdiagnosisinpatientswithsuspectedrheumaticdisease
AT buckandreask wholebody18ffdgpetctcanalterdiagnosisinpatientswithsuspectedrheumaticdisease
AT bleythorstena wholebody18ffdgpetctcanalterdiagnosisinpatientswithsuspectedrheumaticdisease
AT guggenbergerkonstanzev wholebody18ffdgpetctcanalterdiagnosisinpatientswithsuspectedrheumaticdisease
AT wernerrudolfa wholebody18ffdgpetctcanalterdiagnosisinpatientswithsuspectedrheumaticdisease